Sarah Ellis

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

E. Berns, K. Khanna, R. Pearson, 2020, Nature Communications.

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

E. Berns, C. Scott, K. Khanna, 2020, Nature Communications.

RAF1 rearrangements are common in pancreatic acinar cell carcinomas

S. Fox, S. Grimmond, C. Scott, 2020, Modern Pathology.

Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian Cancer

E. Berns, C. Scott, K. Khanna, 2019, bioRxiv.

Heat-induced Alterations in the Localization of HSP72 and HSP73 as Measured by Indirect Immunohistochemistry and Immunogold Electron Microscopy

R. Anderson, S. Ellis, M. Killender, 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer

P. Madhamshettiwar, R. Pearson, R. Hannan, 2020, British Journal of Cancer.

The polarity protein PARD3 and cancer

F. Atashrazm, Sarah Ellis, 2021, Oncogene.

Targeting RNA Polymerase I transcription synergises with TOP1 inhibition in potentiating the DNA damage response in high-grade serous ovarian cancer

P. Madhamshettiwar, R. Pearson, R. Hannan, 2019, bioRxiv.